Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

4 Nov 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Rexahn Pharmaceuticals, Inc. announced today that it has completed its previously announced Registered Direct Offering of common stock and warrants. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for this transaction.

26 Oct 2009

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Adam Kluger Public Relations (www.adamklugerpr.com) announced today that Dr. Dennis Lin, MD (www.drdennismd.com) has retained the New York based boutique PR firm to provide media support and to promote his psychiatric practice which specializes in sexology, sexual relationships, interpersonal difficulties and couples therapy.

26 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Sexual dysfunction in cancer survivors rarely addressed by internists

Few internists who care for cancer survivors address issues of sexual dysfunction with their patients, according to a study led by Massachusetts General Hospital (MGH) researchers. In their article appearing in a November 2009 cancer survivor supplement to the Journal of General Internal Medicine, now available online, the investigators report that more than half the internists responding to a survey indicated they rarely or never discussed sexual problems with their patients who had survived cancer.

22 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Studies show that physiotherapy can help relieve symptoms of prostatitis

Prostatitis is no picnic. It is a urological condition which causes infection or inflammation of the prostate gland. It is a fairly common health concern, especially for men under 50 and can seriously affect quality of life including sexuality and intimate relationships. However, new research regarding the benefits of physiotherapy in treating prostititis is promising.

14 Oct 2009

Stockholders approve BioSante Pharmaceuticals–Cell Genesys merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.

1 Oct 2009

Sexual satisfaction and general well-being linked: Study

Pre- and post-menopausal women who self-rated themselves as being sexually satisfied had a higher overall psychological well-being score and scores for "positive well-being" and "vitality," compared with sexually dissatisfied women in a study of 295 women sexually active more than twice a month. The study, published today in The Journal of Sexual Medicine, also uncovered a positive association between age and well-being, but a negative association for general health.

30 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

BioSante and Cell Genesys encourage stockholders to vote shares

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

18 Sep 2009

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

18 Sep 2009

Multi-topic, hour-long series hosted by a cardiac surgeon premiers today

"The Dr. Oz Show," a high octane, multi-topic hour-long series hosted by trusted health expert, best-selling author, and world-renowned cardiac surgeon Dr. Mehmet Oz, premieres in syndication today (check local listings). Episodes airing during its premiere week feature two of the recently announced "Core Team Oz" guest contributors, fashion and style expert Tim Gunn ("Project Runway") and fitness specialist Bob Harper ("The Biggest Loser"). Also debuting this week as a member of Core Team Oz is "America's vet," Dr. Marty Becker, the popular author and regular veterinary contributor on ABC-TV's "Good Morning America."

14 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.

8 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Sexual dysfunction in cancer survivors rarely addressed by internists

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

Studies show that physiotherapy can help relieve symptoms of prostatitis

Stockholders approve BioSante Pharmaceuticals–Cell Genesys merger

Sexual satisfaction and general well-being linked: Study

Rexahn and Teva sign license and stock purchase agreements

BioSante and Cell Genesys encourage stockholders to vote shares

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

Multi-topic, hour-long series hosted by a cardiac surgeon premiers today

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Labopharm to present its novel trazodone formulation data

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in